NASDAQ:IFRX

InflaRx Q4 2024 Earnings Results & Report

InflaRx logo
$1.15 -0.03 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 -0.03 (-2.52%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$0.09 versus the -$0.27 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

InflaRx EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

InflaRx Revenue Results

Actual Revenue
N/A
Expected Revenue
$125 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

InflaRx Q4 2024 Earnings FAQ

InflaRx (NASDAQ:IFRX) reported earnings of -$0.09 per share for Q4 2024, beating the consensus estimate of -$0.27. The report was announced on Thursday, March 20, 2025.

InflaRx Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
InflaRx (IFRX) AI Stock Analysis
InflaRx Stock Gets Stronger EPS Forecast from HC Wainwright
See More InflaRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InflaRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InflaRx and other key companies, straight to your email.

About InflaRx

InflaRx (NASDAQ:IFRX) is a biotechnology company that develops therapies for inflammatory and autoimmune diseases. Its research focuses on the complement system, a part of the immune system that can contribute to inflammation and tissue damage.

The company’s lead antibody, vilobelimab, targets the complement protein C5a. In 2023, the U.S. Food and Drug Administration granted emergency use authorization for vilobelimab, marketed as Gohibic, for certain hospitalized adults with COVID-19. InflaRx is also investigating the drug in other inflammatory conditions.

Founded in 2007, InflaRx is headquartered in Jena, Germany, and has operations in the United States. Co-founder Niels C. K. Riedemann has served as the company’s chief executive officer.

View InflaRx Profile